drugset / Trial / NCT03548415
Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study was to assess the safety, tolerability, and efficacy of IONIS-GHR-LRx in up to 60 participants with acromegaly.
Timeline
- Start
- 2018-09-13
- Primary completion
- 2021-02-18
- Completion
- 2021-04-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IONIS GHR-LRx | Antisense oligonucleotide | 60 mg | Subcutaneous |
| Subject | IONIS GHR-LRx | Antisense oligonucleotide | 80 mg | Subcutaneous |
| Subject | IONIS GHR-LRx | Antisense oligonucleotide | 120 mg | Subcutaneous |
| Subject | IONIS GHR-LRx | Antisense oligonucleotide | 160 mg | Subcutaneous |